Exosome Diagnostic and Therapeutic Market to Reach $2.9 Bn, Globally, by 2030 at 29.4% CAGR: Allied Market Research – QNT Press Release


Increase in use of multifunctional property of exosome therapy for chronic heart failure, Alzheimer disease, Parkinson’s disease, and cancer drive the growth of the global exosome diagnostic and therapeutic market.

PORTLAND, Ore., May 30, 2022 /PRNewswire/ –Allied Market Research published a report, titled, “Exosome Diagnostic and Therapeutic Market by Application (Diagnostic, Therapeutic), by Product (Instrument, Reagent, and Software) by End User (Cancer Institute, Hospital, Diagnostic Center, Others): Global Opportunity Analysis and Industry Forecast, 2020-2030.” According to the report, the global exosome diagnostic and therapeutic industry was estimated at $224.34 million in 2020, and is anticipated to hit $2.9 billion by 2030, registering a CAGR of 29.4% from 2021 to 2030.

Download Sample PDF at: https://www.alliedmarketresearch.com/request-sample/1723

Determinants of growth-

Increase in use of multifunctional property of exosome therapy for chronic heart failure, Alzheimer’s disease, Parkinson’s disease, and cancer drive the growth of the global exosome diagnostic and therapeutic market. On the other hand, rise in demand for drug therapies and surge in R&D activities in the pharmaceutical and biopharmaceutical fields supplement the market growth even more. Moreover, surge in potential application of exosomes in cancer diagnosis and development of translational precision medicines are expected to create lucrative opportunities in the industry.

Covid-19 scenario-

  • Rapid spread of Covid-19 heightened the need for molecular diagnosis, thus impacting the global exosome diagnostic and therapeutic market positively.
  • This trend is pretty likely to continue till the pandemic is completely over.

The diagnostic segment to dominate by 2030-

Based on application, the diagnostic segment accounted for more than two-thirds of the global exosome diagnostic and therapeutic market share in 2020, and is anticipated to rule the robust by 2030. The same segment would also cite the fastest CAGR of 29.5% throughout the forecast period, due to rise in incidence of chronic disease and surge in demand for early diagnosis.

Specific Requirement on COVID-19? Ask to…

Full story available on Benzinga.com



Source link

Recommended For You

About the Author: News Center